AIA's MCV risk has largely been priced in, with focus shifting to ex-MCV growth and cash generation

Overview

This report focuses on AIA Group Ltd's recent share price volatility, regulatory concerns around Hong Kong MCV business, the resilience of ex-MCV business growth, and relative positioning. J.P. Morgan believes that although MCV-related risks will continue to create pressure, after the share price has fallen back to 1.1x FY27E P/EV, the market has largely priced in that risk, and the debate should now shift from 'whether MCV risk exists' to 'whether AIA's broader growth and cash generation capabilities are being excessively discounted.'

Core views

The core views are: first, AIA's valuation is close to the near-term bottom of 1.0x FY27E P/EV, with the MCV shock significantly discounted by the market; second, cash flow driven by the in-force book is more resilient than the scenario implied by the share price, and a slowdown in new MCV sales mainly affects incremental NBV rather than existing cash flow; third, non-MCV markets such as Mainland China, India, and Thailand are expected to support double-digit group growth; fourth, 1H26 results and regulatory clarity in August may become short-term catalysts, but ahead of the summer earnings season, the report prefers the relative risk-reward of China Life-H and Ping An-H.

Analysis framework

The report uses a combination of valuation re-rating, scenario sensitivity, regional NBV breakdown, and relative positioning comparison. On valuation, it compares the current 1.1x FY27E P/EV with the historical average of 1.7x and the historical low of 1.0x; on scenarios, it assesses the impact of removing 50% of new MCV business on NBV and EV; on growth, it breaks down markets including Hong Kong MCV, ex-MCV, Mainland China, India, and Thailand; on positioning, it compares the attractiveness of AIA versus China Life-H and Ping An-H in terms of dividend yield, life insurance sales momentum, and FY26E P/E.

Methodology notes

• Valuation frameworkMulti-stage growth model

  Forecast NBV by region separately and aggregate for valuation

  J.P. Morgan's Dec-26 target price of HK$112 is derived from a multi-stage growth model, forecasting NBV separately for each geographic market, implying FY26E P/EV of 1.8x, a group new business multiple of 11x, and corresponding to 19x FY26E price/OPAT.

• Sensitivity analysisMCV downside scenario

  50% of new MCV business removed

  The report evaluates the impact on FY26E/FY27E NBV growth, group EV, and cash flow if scenarios such as broker channel closure cause 50% of new MCV business to disappear, concluding that the EV impact would be less than 1%, with the main risk being a slowdown in new business contribution.

• Relative valuationP/EV and P/OPAT comparison

  Compare AIA's current valuation with its historical range and earnings multiples

  AIA currently trades at about 1.1x FY27E P/EV, below the historical average of 1.7x and close to the historical low of 1.0x; it also trades at about 12x FY27E P/OPAT, while the target price corresponds to 19x FY26E price/OPAT.

• Regional growth breakdownNBV contribution forecast

  Observe whether ex-MCV growth by market can offset pressure from Hong Kong MCV

  The report focuses on tracking Mainland China NBV growth, Tata AIA APE scale, and markets such as Thailand to judge whether ex-MCV business is sufficient to support group growth and re-rating.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• AIA Group Ltd (01299.HK)

  Core covered name

  Strengths

  A leading life insurance group in Asia ex-Japan, with large-scale ex-MCV business, relatively resilient cash generation from the in-force book, and potential growth catalysts in Mainland China and India.

  Weaknesses

  Hong Kong MCV business is affected by expectations of tighter cross-border regulation, short-term market sentiment is under pressure, and continued re-rating requires clearer earnings and regulatory catalysts.

  Comparison

  The current 1.1x FY27E P/EV is below the historical average of 1.7x and close to the historical low of 1.0%; relative to China Life-H and Ping An-H, the report believes its downside may be supported by a valuation floor, but its near-term relative risk-reward is not as favorable as Mainland life insurers.

  Risks

  Slower new MCV sales, Hong Kong and China new business below expectations, free surplus generation below expectations, and Asian financial market or political volatility lasting longer than expected.

• China Life Insurance - H (2628.HK)

  Relative positioning comparison name

  Strengths

  Among OW names, the report prefers it heading into the summer earnings season, citing about a 3% dividend yield, life insurance sales momentum, and valuation of about 5x FY26E P/E.

  Weaknesses

  The report does not elaborate on the company's standalone fundamentals and mainly uses it as a relative positioning reference for AIA.

  Comparison

  Relative to AIA, China Life-H is considered more attractive on short-term risk-reward, especially ahead of the earnings season.

  Risks

  China life insurance sales, capital market volatility, and changes in sector valuation may still affect performance.

• Ping An Insurance Group - H (2318.HK)

  Relative positioning comparison name

  Strengths

  Among OW names, the report prefers it heading into the summer earnings season, mentioning about a 6% dividend yield, double-digit life insurance sales momentum, and valuation of about 6x FY26E P/E.

  Weaknesses

  The report does not elaborate on the company's standalone fundamentals and mainly uses it as a relative positioning reference for AIA.

  Comparison

  Relative to AIA, Ping An-H is considered more attractive on short-term risk-reward, especially ahead of the earnings season.

  Risks

  The sustainability of life insurance sales, market volatility, and changes in investor valuation of the China insurance sector may affect the share price.

Key data

• AIA current priceHK$76.50As of the close on June 15, 2026.
• Target priceHK$112.00Dec-26 target price, based on a multi-stage growth model.
• RatingOverweightThe report conclusion is to maintain OW.
• Recent share price performance-7.5%AIA fell 7.5% over the past two weeks, while the HSI fell 2.2% over the same period.
• Current valuation1.1x FY27E P/EVCompared with the historical average of 1.7x and the historical low of 1.0x.
• MCV share of group NBV21%The report believes MCV is important but not the group's sole source of growth.
• Ex-MCV business shareapproximately 80%The report says about 80% of the group's ex-MCV business is still broadly running according to plan.
• FY26E/FY27E OPAT growth10% / 12%J.P. Morgan maintains this OPAT YoY growth forecast.
• FY26/FY27/FY28 NBV growth forecast13% / 19% / 17%The report expects group NBV to maintain double-digit growth from FY26 to FY28.
• Scenario of removing 50% of new MCV businessFY27E consensus NBV growth falls from 15% to 12%; FY26E falls from 15% to 9%The report believes this is a mild reset rather than a major downward revision to group EV.
• Impact on group EVless than 1%Estimated impact under the scenario where 50% of new MCV business is removed, with other conditions unchanged.
• Tata AIA FY25 APEmore than US$1bnEquivalent to 16% of AIA Hong Kong's APE scale.
• Tata AIA 5M26 new life sales growth19% oyaThe India business is viewed as a potentially more visible share price catalyst.
• Mainland China NBV contribution forecast24% in 2026E, 30% in 2028EThe report expects AIA Mainland China's NBV CAGR to be 31% from 2026 to 2028.

Impact & implications

If the report's judgment is correct, AIA's current share price looks more like an excessive discount for MCV regulatory risk than a full reflection of the group's long-term value. Whether the share price can continue to re-rate in the short term depends on whether 1H26 results show double-digit growth, whether the August reporting period provides clearer regulatory information, and whether growth in India and Mainland China can strengthen market confidence in ex-MCV business. At the same time, the report notes that ahead of the summer earnings season, the relative risk-reward of large Mainland China life insurers may be more attractive.

Risks

• Further tightening of Hong Kong cross-border regulation, causing a larger-than-expected slowdown in new MCV sales.
• New sales in Hong Kong SAR/China coming in below expectations, affecting NBV growth and market confidence.
• Free surplus or distributable earnings generation from the in-force business coming in below expectations.
• Financial market or political volatility in Asia ex-Japan lasting longer than expected.
• 1H26 results or August regulatory communication failing to provide sufficiently clear upside catalysts.
• If an increased stake in India or more detailed disclosure does not occur, the India business catalyst for the share price may be delayed.

What to watch

• Whether 1H26 results deliver double-digit financial growth.
• Further clarity during the August reporting period on Hong Kong MCV and cross-border regulation.
• Whether AIA Mainland China's NBV growth approaches the report's expected 31% CAGR for 2026 to 2028.
• Whether Tata AIA continues to expand APE scale, and whether AIA increases its stake or discloses more operating data.
• Under the scenario where 50% of new MCV business is removed, whether the market accepts the judgment that the impact on group EV is less than 1%.
• The relative performance of AIA versus China Life-H and Ping An-H before and after the summer earnings season.